Moreover, blocking CD47-SIRPα interaction with an antibody specific for human SIRPα enhanced killing in vitro by macrophages of HER2+ breast cancer cells previously opsonized with the anti-HER2 monoclonal antibody, trastuzumab (206). Here, SIRPA is linked to breast cancer.